Navigation Links
Nepstar Chain Drugstore (NPD) Greenshoe Fully Exercised
Date:11/15/2007

SHENZHEN, China, Nov. 15 /Xinhua-PRNewswire-FirstCall/ -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD) ("Nepstar" or "the Company"), the largest retail drugstore chain in China based on the number of directly operated stores, announced today that the underwriters of the Company's initial public offering ("IPO") have exercised their greenshoe option in full to purchase 3,093,750 American Depositary Shares ("ADSs") from the Company at the IPO price of US$16.20 per ADS less the underwriting discount. The option was granted in connection with the Company's IPO, which was priced on November 8, 2007.

Including proceeds from the exercise of the greenshoe option, gross proceeds from the Company's IPO would increase to approximately US$384.2million.

Jiannong Qian, Nepstar's Chief Executive Officer, said: "We are delighted that investors have received our ADSs warmly. The funds raised from our IPO will enable us to further expand our store network and take other measures to reinforce our leading position in China's retail drugstore industry."

Goldman Sachs (Asia) L.L.C. was the sole global coordinator of the offering. Goldman Sachs (Asia) L.L.C. and Merrill Lynch, Pierce, Fenner & Smith Incorporated were the joint bookrunners. CLSA Limited was a co-manager of the offering.

Nepstar's registration statement relating to these securities has been declared effective by the United States Securities and Exchange Commission. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of the securities is made only by means of a prospectus forming a part of the effective registration statement. A copy of the prospectus relating to the offering may be obtained by contacting Goldman Sachs & Co. by mail, Attn: Prospectus Department, 85 Broad Street, New York, NY 10004, facsimile: +1-212-902-9316, email: prospectus-ny@ny.email.gs.com.

For more information, please contact:

In Shenzhen:

Lucia Qian

China Nepstar Drugstore Chain Ltd

Tel: +86-755-2641-4065

Email: qianrt@nepstar.cn

In New York:

Ivette Almeida

The Global Consulting Group

Tel: +1-646-284-9455

Email: ialmeida@hfgcg.com

In Hong Kong:

Bruce Shu

Citigate Dewe Rogerson

Tel: +852-2533-4607

Email: bruce.shu@citigate.com.hk


'/>"/>
SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. China Nepstar Chain Drugstore (NPD) Begins Trading on NYSE
2. With the Largest-Ever Buyout of a National Nursing Home Chain Pending ... New York Times Exposes Harm to Seniors After Private Equity Buyouts of Nursing Homes
3. NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains
4. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
5. SEIU Launches Multi-State Grassroots Campaign Calling on the Carlyle Group to Put Care Above Profits in Buyout of Nations Largest Nursing Home Chain
6. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
7. DoD and VA to Reduce Healthcare Supply Chain Costs
8. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
9. PCMA Statement on the Independent Drugstore Lobby Agenda
10. drugstore.com and Revolution Health Group Announce Breakthrough Deal
11. drugstore.com, inc. to Announce Third Quarter 2007 Results During Conference Call on Monday, October 22, 2007 at 5:00 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Semrock’s highly popular SearchLight ... online modeling resource for fluorescence microscopists and optical system designers, enabling The Right ... years spanning the globe, SearchLight has become a tremendously popular tool for the ...
(Date:4/27/2017)... Austin, TX (PRWEB) , ... April 27, 2017 ... ... released its all natural deodorant. On the heels of Thinksport’s award-winning sunscreen they’ve ... safe, non-toxic deodorant that actually works! , Countless deodorants flood the aisles that ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product ... oil many times purer and more potent than the market has seen before. Swissx ... Switzerland, as well as a patented chromatography process for extraction, to produce its CBD ...
(Date:4/26/2017)... ... 26, 2017 , ... Journal of Oral Implantology – Tooth loss ... overall dental health, including complications with speech, eating, and overcompensation of mouth due to ... lost teeth. As the number of tooth replacements increase, it is imperative to design ...
(Date:4/26/2017)... TX (PRWEB) , ... April 26, 2017 , ... ... confer the distinction of Customer Excellence upon National Registry of Emergency Medical ... “Customer Engagement drives Financial Performance,” said Dr. Jan G. West, Ph.D. , ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)... 2017 Research and Markets has ... and Market Prospects: Addressing Production Complexities Through Risk Management ... ... Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through ... assessment of the current trends in the global biosimilars ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: